论文部分内容阅读
目的:观察消瘿方治疗桥本甲状腺炎(hashimoto thyroditis,HT)的临床疗效及其对患者血清肿瘤坏死因子-α(TNF-α)水平的影响。方法:将符合纳入标准的80例HT患者随机分为治疗组(40例)和对照组(40例),治疗组予消瘿方口服,对照组予优甲乐口服,疗程均为12周。评价两组患者的临床疗效,检测并比较两组患者的血清甲状腺球蛋白抗体(TGAb)、甲状腺过氧化物酶抗体(TPOAb)及TNF-α水平。结果:治疗后,治疗组和对照组的临床总有效率分别为82.50%和41.03%,组间临床疗效比较,差异有统计学意义(P<0.05)。治疗后,治疗组患者的TPOAb、TGAb水平较治疗前均显著降低(P<0.05);对照组患者的TPOAb、TGAb水平与治疗前比较,差异无统计学意义(P>0.05);两组患者的TPOAb、TGAb治疗前后差值比较,其差异有统计学意义(P<0.05)。治疗后,治疗组患者的血清TNF-α水平显著下降(P<0.05),且治疗组患者的TNF-α水平低于对照组(P<0.05)。结论:消瘿方治疗HT具有较好的临床疗效,且能明显降低患者的血清TNF-α水平,改善患者的自身免疫性损害。
Objective: To observe the curative effect of Xiaoyu Recipe on Hashimoto thyroditis (HT) and its effect on serum level of tumor necrosis factor-α (TNF-α). Methods: Eighty HT patients who met the inclusion criteria were randomly divided into treatment group (40 cases) and control group (40 cases). The treatment group was given Xiaoxiao Recipe and the control group was treated with Euthyrox. The treatment course was 12 weeks. The clinical efficacy of the two groups was evaluated. The levels of serum thyroglobulin antibody (TGAb), thyroid peroxidase antibody (TPOAb) and TNF-α were detected and compared between the two groups. Results: After treatment, the total clinical effective rates of the treatment group and the control group were 82.50% and 41.03%, respectively. There were significant differences in clinical efficacy between the two groups (P <0.05). After treatment, the levels of TPOAb and TGAb in the treatment group were significantly lower than those before treatment (P <0.05). The levels of TPOAb and TGAb in the control group were not significantly different from those before treatment (P> 0.05) The differences of TPOAb and TGAb before and after treatment were statistically significant (P <0.05). After treatment, the level of TNF-α in the treatment group was significantly decreased (P <0.05), and the level of TNF-α in the treatment group was lower than that in the control group (P <0.05). Conclusion: Xiaoyan Recipe treat HT has better clinical curative effect, and can significantly reduce the level of serum TNF-α and improve the autoimmune damage of the patients.